Yahoo Finance

Morgan Stanley (MS) initiated equal weight coverage on healthcare company Novo Nordisk (NVO), citing the potential in the global obesity market.

While Novo's stock dropped slightly, the firm sees opportunities in obesity treatment but warns market expectations may be too high. Questions remain about pricing and government negotiations, affecting both Novo and its competitors, including Eli Lilly (LLY).

Madison Mills and Seana Smith break down the details on Catalysts.

To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

This post was written by Josh Lynch